Compugen Ltd. (NASDAQ: CGEN)
today announced the appointment of Mr. Avihai Shen as Interim Chief
Financial Officer, replacing Ms. Dikla Czaczkes Axselbrad.
Dr. Anat Cohen-Dayag, Compugen’s President and CEO, stated, “The Company
and Dikla agreed that Dikla would step down from her position as the
Company’s CFO. We thank her for her contributions and wish her every
success in her future endeavors.”
Mr. Shen recently replaced Ms. Czaczkes Axselbrad at Compugen while she
was on maternity leave and therefore is fully capable of stepping in
immediately as the Company’s interim CFO. Mr. Shen has extensive
experience as a chief financial officer for both public and private
companies. Prior to his activities at Compugen, Mr. Shen has served as
CFO at Delek Energy US, Retalix US and Arotech Corp. He began his career
as a certified public accountant with Ernst and Young.
About Compugen
Compugen is a leading drug discovery company focused on therapeutic
proteins and monoclonal antibodies to address important unmet needs in
the fields of immunology and oncology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
silico (by computer) prediction and selection of product candidates,
which are then advanced in its Pipeline Program. The Company's business
model includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. Compugen’s
wholly-owned U.S. subsidiary located in South San Francisco is
developing oncology and immunology monoclonal antibody therapeutic
candidates against its drug targets. For additional information, please
visit Compugen's corporate website at http://www.cgen.com/.
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“potential,” “believes,” and “intends,” and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different from
any future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks and other factors
are discussed in the "Risk Factors" section of Compugen’s Annual Report
on Form 20-F for the year ended December 31, 2013 as filed with the
Securities and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this
release and should not be relied upon as representing its views as of
any subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.
Copyright Business Wire 2014